Purchase Order HHSF223201510340A

<p>The U.S. Food and Drug Administration (FDA) awarded a $41,184.00 firm fixed price purchase order to Alomone Lab LTD, a for-profit organization located in Israel, for the procurement of reagents for electrophysiology studies. This sole source award, which has an ultimate completion date of April 29, 2025, was made by the FDA's Office of Acquisition and Grants Services. No set-aside designation was used for this contract.</p>

The Food and Drug Administration awarded a $50.8K firm fixed price purchase order to Brightfield Group LLC for an exploratory behavioral economics study, with performance in Calverton, Maryland and an ultimate completion date of June 30, 2025. This modification de-obligates funds, cancels the non-funded second item, and closes out the contract. The award carries no set-aside designation and was issued directly to the prime contractor without identified subcontractors. Brightfield Group LLC is...

The Department of Health and Human Services Food and Drug Administration awarded a $2,877,830 firm fixed price delivery order contract to Biopharma Services USA Inc. for NASAL PHARMACOKINETIC (PK)PHARMACODYNAMIC (PD) STUDIES OF ORAL COMBINATION PRODUCTS CONTAINING OPIOID AGONISTS AND ANTAGONISTS. As a foreign owned, self-certified small disadvantaged business, Biopharma Services USA will conduct the in vivo study of generic drug products in human subjects to fulfill the FDA's major program of...

This is a new task order awarded under an existing Indefinite Delivery Indefinite Quantity (IDIQ) contract (HHSF223201610004I) with the Department of Health and Human Services Food and Drug Administration (FDA). The task order, valued at $2,470,791.00, is for a Pharmacokinetic (PK) study of opioid drug products following oral ingestion of chewed products. The study falls under the FDA's In Vivo Study of Generic Drug Products in Human Subjects program. The contract is a Firm Fixed Price...

This is a firm fixed price contract awarded by the Department of Health and Human Services Food and Drug Administration to Oxford Nanopore Technologies Inc., a foreign-owned, for-profit biotechnology company, for the lease of a sensitive long fragment DNA sequencing device. The contract has a potential value of $88,755.00 and a completion date of September 29, 2027. There is no set-aside designation for this award. The original solicitation was a combined synopsis/solicitation posted on May...

This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services (HHS), to SPT Labtech LIMITED, a foreign-owned for-profit manufacturer located in the United Kingdom. The contract, valued at $112,580.00, is for the delivery of a liquid handling robot to support critical research efforts at FDA facilities. This award has not been designated as a set-aside contract. Based on the vendor's history, SPT...

The Department of Health and Human Services Food and Drug Administration awarded a $43,337.06 firm fixed price delivery order to Pacific Biosciences of California, Inc. under the agency's indefinite-delivery/indefinite-quantity contract 75F40121D00007. The delivery order is for the purchase of specific supplies and reagents for use with Pacific Biosciences' PacBio Sequel IIE long-read DNA/RNA sequencer to support the FDA's regulatory science programs. Performance will occur in Laurel, Maryland...

The Department of Health and Human Services Food and Drug Administration awarded a $169,918.01 firm fixed price delivery order contract to We Pharma, Inc. of Morrisville, North Carolina. The purpose of this requirement is to obtain currently marketed drug products for FDA research studies. We Pharma will provide the requested products to the FDA under this contract, which has a completion date of September 29, 2021. No set-aside designation was used for this award made on September 30, 2020.

This is a definitive contract awarded by the Food and Drug Administration (FDA) to the Department of Health, doing business as the Medicines &amp; Healthcare Products Regulatory Agency (MHRA), a UK government agency. The contract, valued at $2,816,500.00, is for the recompete of the General Practice Research Division within the MHRA. It is a firm fixed price contract with no set-aside designation. The contract provides access to the Clinical Practice Research Datalink (CPRD) database and...

The Food and Drug Administration (FDA) awarded a $527,318.00 definitive contract to Uppsala Universitet, a Swedish educational institution, to conduct research and development on model-integrated strategies for bioequivalence evaluation of drugs with high variability and/or long half-life. This contract was awarded under the FDA's Broad Agency Announcement, which seeks proposals to advance regulatory science in various areas. The contract has no set-aside designation and is intended to support...